Table 2. Demographic and transplant characteristics.
| Variable | N (%) |
|---|---|
| N | 470 (100) |
| Recipient Age at Transplant (Years) | |
| <20 | 133 (28) |
| 21 – 40 | 109 (23) |
| >40 | 228 (49) |
| Median age (range), years | 35.7 (0.7 - 69.8) |
| Race | |
| African American | 14(3) |
| Asian | 18(4) |
| Caucasian | 404(86) |
| Hispanic | 13(3) |
| Native American | 4(1) |
| Unknown | 10(2) |
| Mixed | 7(1) |
| Diagnosis | |
| Acute lymphoid leukemia | 92 (20) |
| Acute myeloid leukemia | 151 (31) |
| Chronic myeloid leukemia | 73 (16) |
| Lymphoma | 78 (16) |
| Myelodysplastic syndrome | 40 (9) |
| Others | 36 (8) |
| Disease Status at Transplant | |
| Complete response | 288 (62) |
| Partial response | 24(5) |
| Relapse / primary induction failure | 118 (25) |
| Myelodysplastic syndrome | 38 (8) |
| Missing | 2 (<1) |
| CMV Serological status | |
| Recipient positive / donor positive | 101 (22) |
| Recipient positive / donor negative | 146 (31) |
| Recipient negative / donor positive | 62 (13) |
| Recipient negative / donor negative | 161 (34) |
| Conditioning | |
| Myeloablative | 378 (80) |
| Reduced Intensity | 92 (20) |
| Donor Type | |
| Sibling | 296 (63) |
| Unrelated donor | 75 (16) |
| Cord blood | 99 (21) |
| Stem Cell Source | |
| Marrow | 145 (31) |
| PBSC | 226 (48) |
| Cord blood | 99 (21) |
| GVHD Prophylaxis | |
| CSA/MMF | 125 (27) |
| CSA/MTX | 244 (52) |
| T-cell depletion | 43 (9) |
| Other | 58 (12) |
|
Follow up in years (Survivors), median
(range) |
3.3 (0.9-8.6) |
Abbreviations CMV: cytomegalovirus; PBSC: peripheral blood stem cell; CSA: cyclosporine; MMF: mycophenolate mofetil; MTX: methotrexate